At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 15 enrolled
Drug / intervention
Losartan 50 mg / HCTZ 12.5 mgdrug
Likely dose
Losartan 50 mg / HCTZ 12.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single Arm, Prospective Study to Evaluate the Safety and Anti-hypertensive Efficacy of Losartan 50 mg / Hydrochlorothiazide (HCTZ) 12.5 mg Combination in Patients With Mild to Moderate Essential Hypertension
In Brief
A Phase 4 clinical trial evaluating Losartan 50 mg / HCTZ 12.5 mg for Hypertension. Completed, enrolled 15 participants.
Detailed Summary
This study is being conducted to evaluate the safety and antihypertensive efficacy of MK-0954A (Losartan 50 mg / Hydrochlorothiazide (HCTZ) 12.5 mg) in participants with mild to moderate essential hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
Primary CompletionJun 2009
First PostedSep 2011
TodayJul 2026
First PostedSep 9, 2011
Enrollment StartAug 1, 2007
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.8 years ago
Interventions
Losartan 50 mg / HCTZ 12.5 mgdrug
Losartan 50 mg / HCTZ 12.5 mg tablet once daily for 12 weeks